Acer Therapeutics Past Earnings Performance
Past criteria checks 0/6
Acer Therapeutics's earnings have been declining at an average annual rate of -3.5%, while the Pharmaceuticals industry saw earnings growing at 8.5% annually. Revenues have been growing at an average rate of 36.6% per year.
Key information
-3.5%
Earnings growth rate
14.7%
EPS growth rate
| Pharmaceuticals Industry Growth | 6.0% |
| Revenue growth rate | 36.6% |
| Return on equity | n/a |
| Net Margin | n/a |
| Last Earnings Update | 30 Jun 2023 |
Recent past performance updates
Recent updates
Acer Therapeutics to develop ACER-801 for post-traumatic stress disorder treatment
Oct 05Acer, Relief's metabolic disorder therapy ACER-001 gets orphan drug status in EU
Aug 12FDA accepts Acer's resubmitted U.S. marketing application for urea cycle disorder therapy
Jul 28Acer resubmits U.S. marketing application for urea cycle disorder therapy
Jul 18Companies Like Acer Therapeutics (NASDAQ:ACER) Can Afford To Invest In Growth
Feb 11
Acer Therapeutics: Deriving Value By Developing Therapies For Rare Diseases
Aug 31We're Not Very Worried About Acer Therapeutics' (NASDAQ:ACER) Cash Burn Rate
May 20Need To Know: Acer Therapeutics Inc. (NASDAQ:ACER) Insiders Have Been Buying Shares
Feb 25Acer Therapeutics completes enrollment in ACER-001 bioequivalence trial for urea cycle disorders
Dec 22Revenue & Expenses BreakdownBeta
How Acer Therapeutics makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 23 | 0 | -39 | 11 | 9 |
| 31 Mar 23 | 0 | -33 | 11 | 11 |
| 31 Dec 22 | 0 | -26 | 13 | 12 |
| 30 Sep 22 | 0 | -21 | 13 | 11 |
| 30 Jun 22 | 0 | -20 | 12 | 10 |
| 31 Mar 22 | 0 | -20 | 11 | 8 |
| 31 Dec 21 | 1 | -15 | 11 | 7 |
| 30 Sep 21 | 1 | -17 | 10 | 8 |
| 30 Jun 21 | 1 | -20 | 11 | 10 |
| 31 Mar 21 | 1 | -23 | 12 | 12 |
| 31 Dec 20 | 0 | -23 | 11 | 12 |
| 30 Sep 20 | 0 | -22 | 11 | 11 |
| 30 Jun 20 | 0 | -21 | 10 | 11 |
| 31 Mar 20 | 0 | -26 | 13 | 12 |
| 31 Dec 19 | 0 | -29 | 15 | 13 |
| 30 Sep 19 | 0 | -33 | 16 | 16 |
| 30 Jun 19 | 0 | -31 | 15 | 15 |
| 31 Mar 19 | 0 | -25 | 12 | 14 |
| 31 Dec 18 | 0 | -21 | 9 | 12 |
| 30 Sep 18 | 0 | -17 | 8 | 9 |
| 30 Jun 18 | 0 | -17 | 8 | 9 |
| 31 Mar 18 | 0 | -15 | 7 | 8 |
| 31 Dec 17 | 0 | -14 | 5 | 9 |
| 30 Sep 17 | 0 | -12 | 3 | 9 |
| 30 Jun 17 | 0 | -11 | 2 | 8 |
| 31 Mar 17 | 0 | -9 | 1 | 8 |
| 31 Dec 16 | 0 | -7 | 1 | 5 |
Quality Earnings: ACER is currently unprofitable.
Growing Profit Margin: ACER is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: ACER is unprofitable, and losses have increased over the past 5 years at a rate of 3.5% per year.
Accelerating Growth: Unable to compare ACER's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: ACER is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (-17.3%).
Return on Equity
High ROE: ACER's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.